Celyad Announces First Quarter 2017 Business Update

Celyad Announces First Quarter 2017 Business Update

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Discover our news

Upcoming events

Jun 2-6, 2017

ASCO 2017

Jun 19-22, 2017

BIO International Convention

Discover all events

Press contacts

Stern Investor Relations (US)

Will O’Connor, Michael Schaffzin

+1 212 362 1200

Celyad

Marine Lhomel
Corporate Communications Manager

+32 (0)10 39 41 94

Consilium Strategic Communications (UK)

Chris Welsh, Chris Gardner

+44 20 3709 5700

NewCap (France)

Nicolas Merigeau, Pierre Laurent

+ 33(0)1 44 71 94 94

Comfi (Belgium)

Gunther De Backer, Sabine Leclercq

+32(0) 2 290 90 91